sorafenib has been researched along with fh535 in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fh535) | Trials (fh535) | Recent Studies (post-2010) (fh535) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 42 | 0 | 40 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT | 1 |
Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V | 1 |
Chacon, E; Cornea, V; Eman, P; Garcia, C; Gedaly, R; Jiang, J; Liu, C; Marti, F; Spear, B; Turcios, L; Watt, DS | 1 |
3 other study(ies) available for sorafenib and fh535
Article | Year |
---|---|
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway | 2014 |
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Topics: Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Humans; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Sulfonamides | 2017 |
Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autophagy; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |